Viewing data from:

RIDAURA

NDA

AURANOFIN | N018689 | LEGACY PHARMA INC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

12 trials from ClinicalTrials.gov, 8 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure NCT02961829	N/A	Completed	Federal University of São Paulo	30	2015-07 → 2020-03
Auranofin for Giardia Protozoa NCT02736968	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	93	2016-11-06 → 2021-03-10
Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome NCT02063698	Phase 2	Completed	Mayo Clinic	30	2014-02-19 → 2016-11-11
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)NCT01419691	Phase 2	Completed	University of Kansas Medical Center	15	2011-09 → 2015-09
Auranofin PK Following Oral Dose Administration NCT02089048	Phase 1	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	15	2014-04-02 → 2015-05-13
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer NCT01737502	Phase 1/2	Completed	Mayo Clinic	29	2014-05-14 → 2023-04-24
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma NCT02770378	Phase 1/2	Completed	University of Ulm	10	2016-11 → 2020-12
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT01747798	Early Phase 1	Completed	Mayo Clinic	10	2012-11-02 → 2015-04-06
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer NCT03456700	Phase 2	Terminated	Mayo Clinic	22	2018-03-30 → 2019-07-31
TB Host Directed Therapy NCT02968927	Phase 2	UNKNOWN	The Aurum Institute NPC	200	2016-11 → 2020-12

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$24.85

per ea

Lowest NADAC/Unit

$24.85

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
54766009306RIDAURA 3 MG CAPSULE	$24.85	EA	Brand	—	2025-12-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 1 NDC (1 FSS)

Lowest Price

$1065.09

Highest Price

$1065.09

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
54766-0093-06RIDAURA 3MG CAP	$1065.09	FSS	Legacy Pharma USA, Inc.	09/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Ridaura (2024)

Total Spending

$922K

Total Claims

635

Beneficiaries

Avg Cost/Unit

$25.91

Spending Trend

$1.3M(2019)→$1.2M(2020)→$1.1M(2021)→$1.1M(2022)→$994K(2023)→$922K(2024)

YoY Change:+1.4%

5yr CAGR:+4.2%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain1 active DMF6 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

VERANOVA LPAURANOFIN

DMF 158032002

LONZA RIVERSIDEInactiveAURANOFIN

DMF 42121981

LEK PHARMACEUTICAL AND CHEMICAL CO DDInactiveAURANOFIN

DMF 82921989

PFANSTIEHL LABORATORIES INCInactiveAURANOFIN

DMF 83891990

MEDICHEM SAInactiveAURANOFIN

DMF 86481990

JOHNSON MATTHEY INCInactiveAURANOFIN

DMF 96581992

SMITHKLINE BEECHAM PHARMACEUTICALSInactiveAURANOFIN

DMF 97481992

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 3MG

RLD

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: May 24, 1985

No patent or exclusivity listings for this strength.